USAR

USA Rare Earth

$6.27

-8.73%
Nov 20, 2026
Bobby Quantitative Model
USA Rare Earth, Inc. is a vertically integrated domestic rare earth magnet supply chain company developing an NdFeB magnet manufacturing plant in the United States alongside rare earth and critical minerals extraction and processing capabilities, operating within the Basic Materials sector's industrial materials niche and deriving maximum revenue internationally. With only 132 employees and a single reportable operating segment, the company is a pre-revenue-scale strategic asset rather than an established producer, positioning itself as a national-security-adjacent platform intended to break China's grip on rare earth magnet supply. The investor narrative has swung violently between government-backing euphoria and execution skepticism: headlines highlight a transformative government-backed deal with purchase contracts, the pending Serra Verde acquisition that could flip the company from cash-burning to cash-flow positive, and groundbreaking on a $1.2 billion South Carolina facility, while offsetting concerns include a massive share overhang, China export restrictions, a legal dispute with MP Materials, and a November downgrade questioning the path to profitable integration. The stock's collapse to near 52-week lows despite a 'strong buy' consensus captures the core debate: whether strategic importance and government support can bridge the gap to commercial-scale, profitable production before dilution and cash burn erode equity value.

People also watch

MP Materials

MP Materials

MP

Analysis
Materion

Materion

MTRN

Analysis
Almirall

Almirall

ALM

Analysis
Critical Metals Corp. Ordinary Shares

Critical Metals Corp. Ordinary Shares

CRML

Analysis
United States Antimony Corporation

United States Antimony Corporation

UAMY

Analysis

BobbyInvestment Opinion: Should I buy USAR Today?

Rating: Hold (speculative, event-driven). The core thesis is that USAR is a national-security-adjacent rare earth magnet platform whose equity value hinges on binary execution events — closing the Serra Verde acquisition, converting government-backed purchase contracts into revenue, and ramping the $1.2 billion South Carolina plant — rather than on current fundamentals, which show Q3 2026 revenue of just $3.002 million against a -$461.8 million TTM free cash flow burn. The unanimous sell-side stance (9 Buy, 0 Hold, 0 Sell, recommendation mean 1.11) with an average target of $29.50 implies +313.7% upside from $7.13, but that gap reflects long-dated strategic value, not near-term earnings support.

Supporting evidence cuts both ways. On the positive side, the balance sheet is nearly debt-free (debt-to-equity 0.0062) with $1.164 billion in cash and a current ratio of 10.17, giving a genuine multi-year runway; the forward PE of 30.34x versus a trailing PE of -3.60x implies the market expects a dramatic earnings inflection consistent with analyst estimated EPS of $1.91 and estimated revenue of $2.90 billion. On the negative side, gross margin of -662.29% in Q3 2026 (gross profit -$19.88 million) means the company sells below cost, the $11.7 million net income was entirely a $148.05 million other-income artifact masking a -$141.44 million operating loss, and shares outstanding rose from 148.1 million at Q4 2025 to 284.9 million at Q3 2026 — roughly 92% dilution in three quarters. The PS ratio of 709.95x and EV/Sales of 163.52x are speculative, not fundamental, and the stock's -50.79% one-year return against a +10.12% SPY confirms idiosyncratic deterioration.

Risks that would invalidate the thesis: (1) Serra Verde integration slipping or proving unprofitable, which would remove the single lever that could flip free cash flow positive; (2) another equity raise at depressed prices to fund the South Carolina buildout, compounding the existing share overhang; and (3) a break below the $6.84 52-week low, which would open fresh downside with no historical floor given the -81.57% max drawdown. This Hold would upgrade to Buy if the company reports positive gross margin and sequential revenue growth above $5.82 million (the Q2 2026 level) alongside confirmed Serra Verde close, and would downgrade to Sell on a sub-$6.84 break or a further large equity issuance. Valuation verdict: the stock is cheap relative to its own history (PS down from 1,372.59x, P/B from 3.58x to 2.37x) but expensive relative to any fundamental anchor — fairly valued only if the transformational scenario materializes, overvalued on current operations.

Sign up to view all

USAR 12-Month Price Forecast

The forward view is genuinely two-sided: the sell-side is unanimously bullish with a $29.50 average target, but the market has repriced the equity down 50.79% over a year because revenue is declining sequentially, gross margin is deeply negative, and dilution is running at roughly 92% over three quarters. The near-debt-free balance sheet with $1.164 billion in cash is the strongest argument for patience, since it removes near-term solvency risk and funds the South Carolina buildout, but it does not by itself create earnings power. The single variable that matters most is whether Serra Verde plus government purchase contracts convert USAR into a cash-generative producer within the next 12 months; until that evidence appears, the stock is likely to trade between the $6.84 low and the mid-teens rather than toward the analyst range. I would upgrade to bullish on confirmed Serra Verde close with positive gross margin and revenue above the $5.82 million Q2 2026 peak, and downgrade to bearish on a decisive break below $6.84 or a further large equity raise at current prices.

Historical Price
Current Price $6.27
Average Target $11.50
High Target $45.00
Low Target $5.33

Wall Street consensus

Most Wall Street analysts maintain a constructive view on USA Rare Earth's 12-month outlook, with a consensus price target around $29.50 and implied upside of +370.5% versus the current price.

Average Target

$29.50

9 analysts

Implied Upside

+370.5%

vs. current price

Analyst Count

9

covering this stock

Price Range

$20 - $45

Analyst target range

Buy
8 (89%)
Hold
1 (11%)
Sell
0 (0%)

Coverage is robust for a company of this profile, with 8 analysts contributing to a consensus that is unanimously bullish: 9 Buy ratings, 0 Hold, and 0 Sell, yielding a recommendation of 'strong_buy' and a recommendation mean of 1.11 (where 1.0 is a strong buy). The average target price of $29.50 implies a staggering +313.7% upside from the current $7.13 — an extraordinary gap that underscores how far the stock has fallen below sell-side expectations. This consensus leans emphatically bullish, but the magnitude of the implied upside relative to a stock down 50.79% over the year suggests analysts are anchoring to long-term strategic value and government-backed contracts rather than near-term fundamentals.

The full target range spans $20.00 to $45.00 — a $25 spread (125% of the low end) that signals very high uncertainty and wide disagreement about execution outcomes. The high target of $45.00 likely assumes successful Serra Verde integration, full South Carolina plant ramp, government purchase-contract revenue materializing, and multiple expansion on a transformed earnings base; the low target of $20.00 still implies +180.5% upside and likely prices in slower integration, continued cash burn, and dilution but not outright failure. Institutional ratings show a pattern of reiterations rather than fresh upgrades — Cantor Fitzgerald maintained Overweight on 2026-11-10, Needham and Roth Capital reiterated Buy in July, and Wedbush/Canaccord have held Outperform/Buy through the year — with no downgrades in the formal ratings list despite the November Motley Fool piece referencing a downgrade. The persistence of bullish ratings against a collapsing share price creates a notable credibility gap, and the wide target dispersion combined with a beta of 2.82 warns that price discovery remains highly inefficient and volatile.

Drowning in data?

Find the real signal!

Bulls vs Bears: USAR Investment Factors

The bear case currently has stronger near-term evidence: revenue is declining sequentially ($5.82M to $3.00M), gross margins are deeply negative at -662%, free cash flow is -$461.8 million TTM, and the stock sits 1.1% above its 52-week low with accelerating downside momentum. The bull case rests almost entirely on forward-looking, binary events — the Serra Verde acquisition closing, government purchase-contract revenue materializing, and the $1.2 billion South Carolina plant ramping — none of which have yet produced earnings. The single most important tension is whether government-backed contracts and Serra Verde can convert USAR into a cash-generative producer before dilution and cash burn erode equity value; resolution of that question, not current fundamentals, will determine the stock's direction. With a beta of 2.82 and a $25 analyst target spread, price discovery remains highly inefficient, so any rally should be treated as counter-trend until production and profitability evidence emerges.

Bullish

  • Unanimous Strong Buy, 314% Upside: All 9 ratings are Buy with zero Hold or Sell, a recommendation mean of 1.11, and an average target of $29.50 implying +313.7% upside from $7.13. Even the lowest target of $20.00 implies +180.5%, meaning the entire sell-side range sits far above the current price.
  • Government-Backed Deal and Purchase Contracts: The transformative government-backed deal with secured funding and purchase contracts drove a 19.2% monthly surge in August 2026 and underpins the strategic thesis. These contracts are the closest thing to revenue visibility the company has, given Q3 2026 revenue of just $3.002 million.
  • Serra Verde Could Flip Cash Flow: The pending Serra Verde acquisition, with government-backed revenue guarantees, is the key lever that could transform USAR from a -$461.8 million TTM free-cash-flow burner into a cash-generative business. Analyst estimated revenue averaging $2.90 billion versus current sales of a few million dollars reflects this step-change expectation.
  • Near Debt-Free Balance Sheet Buys Time: Debt-to-equity of 0.0062 and a current ratio of 10.17, backed by $1.164 billion in cash at Q3 2026, mean there is no near-term solvency crisis. This liquidity runway allows the $1.2 billion South Carolina buildout to proceed without forced distressed financing.

Bearish

  • Falling Knife at 52-Week Lows: The stock trades at $7.13, just 1.1% above its 52-week low of $6.84 and 78.3% below its $32.80 high, with a -81.57% max drawdown. Momentum is accelerating downward: -32.35% in one month and -61.48% in three months, worse than the -50.79% one-year decline.
  • Revenue Collapsing Sequentially: Q3 2026 revenue of $3.002 million fell from $5.821 million in Q2 and $5.698 million in Q1, showing lumpy contract sales rather than a durable ramp. Against a $1.17 billion market cap, the PS ratio of 709.95x and EV/Sales of 163.52x are speculative rather than fundamental.
  • Selling Below Cost, Deep Operating Losses: Q3 2026 gross margin was -662.29% (gross profit -$19.88 million on $3.00 million revenue), deteriorating from -0.70% in Q2, with an operating loss of -$141.44 million and EBITDA of -$138.12 million. The $11.7 million net income was entirely due to a $148.05 million other-income line, not operations.
  • Massive Dilution and Cash Burn: Free cash flow is -$461.8 million TTM, and shares outstanding ballooned from 148.1 million at Q4 2025 to 284.9 million at Q3 2026, with $1.50 billion in common stock issued in Q1 2026 alone. Continued equity issuance to fund the $1.2 billion plant and $191.2 million in acquisitions erodes per-share value.

USAR Technical Analysis

USA Rare Earth is locked in a severe, sustained downtrend, with the current price of $7.13 sitting just 1.1% above its 52-week low of $6.84 and a staggering 78.3% below its 52-week high of $32.80 — effectively trading at the very bottom of its 52-week range (roughly 1% of the range). The 1-year price change of -50.79% and 6-month decline of -68.41% confirm this is a falling-knife setup rather than a value opportunity, with the -81.57% max drawdown underscoring the depth of capital destruction since the March 2025 listing. Positioning near the lows signals capitulation and persistent selling pressure, meaning any bounce should be treated as a counter-trend rally until proven otherwise.

Short-term momentum is accelerating to the downside and diverging sharply from an already weak longer-term trend. The 1-month change of -32.35% and 3-month change of -61.48% are far worse than the 1-year -50.79%, indicating the decline is steepening rather than stabilizing; the most recent session alone saw a -12.62% drop from the $8.16 previous close. Relative strength versus the S&P 500 is deeply negative across every window — -29.30% over 1 month, -57.90% over 3 months, and -60.91% over 1 year — against a SPY that was roughly flat to modestly positive, confirming the weakness is idiosyncratic rather than market-driven. This accelerating divergence signals unresolved selling pressure and no evidence of mean-reversion support yet.

Key technical levels are stark: support rests at the 52-week low of $6.84, just 4.1% below the current $7.13, and a breakdown below that level would open fresh downside with no historical floor. Resistance is anchored at the $32.80 52-week high, but nearer-term overhead supply likely sits at the $10-$11 shelf where the stock traded in late October before its final leg down. With a beta of 2.82, the stock is roughly 182% more volatile than the market, meaning position sizing must be dramatically reduced and stop-losses widened; a short ratio of 4.28 days-to-cover and volume of 17.2 million shares indicate heavy two-way speculation that amplifies gap risk in both directions.

Beta

2.82

2.82x market volatility

Max Drawdown

-80.2%

Largest decline past year

52-Week Range

$6-$33

Price range past year

Annual Return

-48.6%

Cumulative gain past year

PeriodUSAR ReturnS&P 500
1m-38.7%-9.7%
3m-67.4%-9.9%
6m-75.2%-7.5%
1y-48.6%+4.7%
ytd-55.7%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

USAR Fundamental Analysis

The revenue trajectory is nascent and erratic rather than a clean growth story. Most recent Q3 2026 revenue was $3.002 million, down sharply from $5.821 million in Q2 2026 and $5.698 million in Q1 2026, while Q4 2025 posted just $1.643 million and the first three quarters of 2025 reported zero revenue — reflecting a company only just beginning to commercialize. The sequential decline from $5.82M to $3.00M suggests lumpy, contract-driven sales rather than a durable ramp, and with a TTM free cash flow of -$461.8 million against this tiny revenue base, the growth trend does little to offset the scale of cash consumption. The investment case therefore rests entirely on future production capacity (the $1.2 billion South Carolina plant and Serra Verde acquisition) rather than current commercial momentum.

Profitability is deeply negative on an operating basis despite a headline positive net income. Q3 2026 net income of $11.706 million was driven by a $148.05 million total other income line, masking an operating loss of -$141.44 million and EBITDA of -$138.12 million; gross profit was -$19.88 million on a gross margin of -662.29% (reported as -6.6229 in ratio form), meaning the company sells product below cost. The operating margin of -36.22% and net margin of -181.11% (TTM) confirm that core operations are burning cash at an extraordinary rate, with cost of revenue of $22.88 million dwarfing the $3.00 million in revenue. Margins are not stabilizing — the gross margin deteriorated from -0.70% in Q2 to -6.62% in Q3 — and the path to profitability depends on scaling manufacturing utilization that does not yet exist.

Financial health is a tale of two extremes: an almost debt-free balance sheet paired with massive cash burn. Debt-to-equity is a negligible 0.0062 and the current ratio is a very strong 10.17, with $1.164 billion in cash at the end of Q3 2026 — but that cash was raised through equity, with $1.50 billion in common stock issued in Q1 2026 alone, and free cash flow is deeply negative at -$226.2 million for Q3 and -$461.8 million TTM. ROE of -60.40% and ROA of -2.73% reflect the absence of earnings power, and with capital expenditures of $82.5 million in Q3 and $191.2 million in acquisitions, the company is entirely dependent on external financing to fund its buildout. The low leverage is a genuine strength that buys time, but the FCF yield is deeply negative and the equity is being diluted aggressively to sustain operations.

Quarterly Revenue

$3002000.0B

2026-09

Revenue YoY Growth

N/A

YoY Comparison

Gross Margin

N/A

Latest Quarter

Free Cash Flow

$-461789000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Open an Account, get $2 TSLA now!

Valuation Analysis: Is USAR Overvalued?

Because trailing net income is negative (EPS of -$0.255, trailing PE of -3.60), the PE ratio is not meaningful and I have selected the price-to-sales ratio as the primary metric, supplemented by EV/Sales given negative EBITDA (EV/EBITDA of -13.98). The PS ratio of 709.95x is extreme and reflects a revenue base of only a few million dollars against a ~$1.17 billion market cap; the forward PE of 30.34x is the more instructive figure, implying the market expects a dramatic earnings inflection — consistent with analyst estimated EPS averaging $1.91 and estimated revenue averaging $2.90 billion, a roughly 1,000x step-up from current sales. The enormous gap between trailing and forward multiples signals the market is pricing in a transformational, acquisition-and-contract-driven ramp that has yet to materialize.

Peer comparison is difficult given the absence of a clean industry-average multiple in the provided data, but the absolute figures are revealing: a PS of 709.95x and EV/Sales of 163.52x are orders of magnitude above what any established industrial materials producer commands, and even against speculative critical-minerals peers these multiples imply the market is capitalizing future capacity, not current operations. The price-to-book of 2.37x is comparatively modest and reflects the large equity raises inflating book value rather than earnings strength. Any premium here is justified only by strategic scarcity value and government backing — not by demonstrated growth, profitability (net margin -181.11%, gross margin negative), or competitive position, all of which argue the multiple is speculative rather than fundamental.

Historical context shows the valuation has compressed dramatically from its own peak. The PS ratio has fallen from 1,372.59x at Q3 2026 reporting to 709.95x currently, and price-to-book has collapsed from 3.58x at year-end 2025 to 2.37x now, while the stock trades near its 52-week low of $6.84 versus a high of $32.80. This places the stock near the bottom of its own valuation band — which could signal a value opportunity, but given the deteriorating fundamentals (revenue declining sequentially, gross margins turning more negative, and continued heavy cash burn), the compression more likely reflects fundamental deterioration and loss of confidence than a mispricing. The market is repricing the equity downward as the gap between promise and delivery widens.

PE

-3.6x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 2x~45x

vs. Industry Avg

25.2x

Industry PE ~25.2x*

EV/EBITDA

-14.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are severe and quantifiable. Free cash flow is -$461.8 million TTM, with Q3 2026 alone burning -$226.2 million, while revenue was only $3.002 million and gross margin was -662.29%, meaning the company sells product far below cost. Shares outstanding rose from 148.1 million at Q4 2025 to 284.9 million at Q3 2026 — roughly a 92% increase — as $1.50 billion in common stock was issued in Q1 2026 to fund the $1.2 billion South Carolina plant and $191.2 million in acquisitions. The near-zero debt-to-equity of 0.0062 and $1.164 billion cash balance provide a runway, but the company is entirely dependent on external financing, and continued dilution is the most direct threat to per-share value.

Market and competitive risks center on valuation compression and sentiment fragility. The PS ratio of 709.95x and EV/Sales of 163.52x are orders of magnitude above any established industrial materials producer, justified only by strategic scarcity and government backing rather than demonstrated growth or profitability (net margin -181.11%). The stock's beta of 2.82 makes it roughly 182% more volatile than the market, and relative strength versus the S&P 500 is -60.91% over one year against a SPY that rose 10.12%, confirming the weakness is idiosyncratic. Recent news highlights a November downgrade, a legal dispute with MP Materials, China export restrictions, and a massive share overhang — each capable of triggering further multiple compression independent of operating progress.

The worst-case scenario is a chain in which Serra Verde integration slips or proves unprofitable, government purchase-contract revenue fails to materialize on schedule, and the company must raise equity again at depressed prices to fund the South Carolina buildout — diluting existing holders while the stock breaks below its $6.84 52-week low with no historical floor. From the current $7.13, a break of support opens fresh downside, and the -81.57% max drawdown shows how far this equity can fall; a retest of the $6.84 low alone implies roughly -4%, while a move toward the $5 range or below would represent a -30% or worse loss. Even the analyst low target of $20.00 is far above the current price, so the sell-side provides no downside anchor — the realistic bear-case floor is the 52-week low and below.

FAQ

The most severe risk is financial: TTM free cash flow of -$461.8 million against $3.002 million of quarterly revenue, with shares outstanding up from 148.1 million at Q4 2025 to 284.9 million at Q3 2026 (roughly 92% dilution) and $1.50 billion of common stock issued in Q1 2026 alone — another raise at depressed prices would directly erode per-share value. Second is execution and company-specific risk: the Serra Verde integration and the $1.2 billion South Carolina buildout must both succeed, and Q3 2026 gross margin of -662.29% (gross profit -$19.88 million) shows the company currently sells below cost, while the $11.7 million net income was a $148.05 million other-income artifact masking a -$141.44 million operating loss. Third is competitive and legal risk, including the MP Materials legal dispute and China export restrictions that could disrupt supply or sentiment. Fourth is market and macro risk: a beta of 2.82 and -60.91% relative strength versus the S&P 500 over one year mean the stock amplifies any sector rotation or risk-off move, and the $25 analyst target spread ($20-$45) signals that price discovery remains highly inefficient.

The scenario framework assigns a 55% probability to the base case of $8.00-$15.00, a 25% probability to the bear case of $4.50-$6.84, and a 20% probability to the bull case of $29.50-$45.00. The base case is most likely: Serra Verde closes but contributes limited revenue within 12 months, quarterly revenue stays in the $3-6 million band, gross margin remains negative, and at least one more equity raise caps upside — leaving the stock above the $6.84 low but far below the $20.00 analyst low target. The bull case requires confirmed Serra Verde close with government purchase contracts recognized above the $5.821 million Q2 2026 peak and gross margin turning positive, which would make the forward PE of 30.34x and EPS of $1.91 the relevant anchors. The bear case assumes integration slips, revenue fails to materialize, and a fresh raise at depressed prices breaks the 52-week low with no historical floor, implying roughly -4% to -37% from $7.13.

The answer depends entirely on which anchor you use, and that divergence is the heart of the debate. On trailing fundamentals the stock is extraordinarily expensive: the PS ratio is 709.95x and EV/Sales is 163.52x against quarterly revenue of just $3.002 million, with a trailing PE of -3.60x because EPS is -$0.255 and a net margin of -181.11%. On forward numbers it looks far more reasonable: the forward PE of 30.34x rests on analyst estimated EPS of $1.91 and estimated revenue of $2.90 billion, a roughly 1,000x step-up from current sales that assumes Serra Verde and the South Carolina plant deliver. Relative to its own history the multiple has compressed hard — PS from 1,372.59x and P/B from 3.58x to 2.37x — but that compression tracks deteriorating fundamentals rather than a mispricing. The market is therefore paying a premium for future capacity and strategic scarcity, not current earnings; the stock is overvalued on operations and only fairly valued if the transformational scenario materializes.

From a pure risk/reward standpoint, USAR offers an asymmetric but highly uncertain payoff. The 9 Buy / 0 Hold / 0 Sell consensus and $29.50 average target imply +313.7% upside from $7.13, and even the $20.00 low target implies +180.5%, while the near debt-free balance sheet ($1.164 billion cash, debt-to-equity 0.0062) removes near-term solvency risk. Against that, the downside is equally concrete: the stock is 1.1% above its $6.84 52-week low, has a beta of 2.82, and has already suffered a -81.57% max drawdown, with gross margin at -662.29% and TTM free cash flow of -$461.8 million. It is a reasonable speculative buy only for investors who can tolerate a potential -30% or worse drawdown and who size the position as a small option on Serra Verde closing and government contracts converting to revenue; for anyone requiring earnings support or capital preservation, it is not a good buy at this stage.

USAR is best suited to a long-term, high-risk-tolerance holding period of at least 24-36 months, because the thesis depends on multi-year events — closing and integrating Serra Verde, ramping the $1.2 billion South Carolina facility, and converting government-backed purchase contracts into commercial-scale revenue — none of which resolve within a quarter or two. It pays no dividend (payout ratio 0, dividend yield 0) and has no meaningful earnings visibility, with a trailing PE of -3.60x and net margin of -181.11%, so there is no income or valuation floor to support a short-term trade. The beta of 2.82, short ratio of 4.28 days-to-cover, and 17.2 million share volume make it a volatile instrument where short-term moves are driven by news and dilution announcements rather than fundamentals, as shown by the -32.35% one-month and -61.48% three-month declines. Short-term traders face gap risk in both directions; long-term holders should size positions for a potential -30% to -37% drawdown and monitor the $6.84 support level as a thesis-invalidation trigger.